CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) is a publicly traded Gene & Genome Editing Platforms company founded in 2013 and based in Zug, Switzerland.
CRISPR Therapeutics was founded in 2013 and is headquartered in Zug, Switzerland. The company builds gene and genome editing therapies based on CRISPR/Cas9. Its flagship product, Casgevy (exagamglogene autotemcel), is an ex vivo cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, made by editing a patient's own CD34+ hematopoietic stem cells and delivered as a one-time infusion. Casgevy is co-developed with Vertex, which leads manufacturing and commercialization, while CRISPR shares development costs and profits. The company's pipeline includes CTX310, an investigational in vivo therapy delivered through its proprietary lipid nanoparticle platform that targets ANGPTL3 in the liver to lower triglycerides and LDL cholesterol. CRISPR Therapeutics is listed on NASDAQ under the ticker CRSP, and its headcount falls in the 201–500 range. Its co-founders are Emmanuelle Charpentier, Rodger Novak, and Shaun Foy.
CRISPR Therapeutics is one of the organizations behind Casgevy, a CRISPR/Cas9-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia that has received approvals in the US, UK, EU, and several other countries. The company's co-development arrangement with Vertex covers a medicine that edits a patient's own stem cells at the BCL11A erythroid enhancer to raise fetal hemoglobin production. Its CTX310 program applies the same editing approach in vivo, using a lipid nanoparticle delivery platform, to target ANGPTL3 for cardiovascular and cardiometabolic disease.
At a glance
Total raised
Undisclosed
Headcount
201-500
Headquarters
Zug
SwitzerlandFounded
2013
Status
Public
Subsector
Funding history
Total raised
—
Rounds tracked
0
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.